Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/LYN_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/LYN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LYN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LYN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LYN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0001776 | Oral cavity | OSCC | leukocyte homeostasis | 48/7305 | 87/18723 | 1.60e-03 | 7.62e-03 | 48 |
GO:00486784 | Oral cavity | OSCC | response to axon injury | 46/7305 | 83/18723 | 1.76e-03 | 8.31e-03 | 46 |
GO:00380942 | Oral cavity | OSCC | Fc-gamma receptor signaling pathway | 19/7305 | 28/18723 | 1.88e-03 | 8.84e-03 | 19 |
GO:00622076 | Oral cavity | OSCC | regulation of pattern recognition receptor signaling pathway | 56/7305 | 105/18723 | 1.99e-03 | 9.23e-03 | 56 |
GO:00022184 | Oral cavity | OSCC | activation of innate immune response | 31/7305 | 52/18723 | 2.08e-03 | 9.59e-03 | 31 |
GO:00603269 | Oral cavity | OSCC | cell chemotaxis | 146/7305 | 310/18723 | 2.13e-03 | 9.80e-03 | 146 |
GO:0060251 | Oral cavity | OSCC | regulation of glial cell proliferation | 23/7305 | 36/18723 | 2.19e-03 | 9.95e-03 | 23 |
GO:00022243 | Oral cavity | OSCC | toll-like receptor signaling pathway | 63/7305 | 121/18723 | 2.36e-03 | 1.04e-02 | 63 |
GO:190303910 | Oral cavity | OSCC | positive regulation of leukocyte cell-cell adhesion | 115/7305 | 239/18723 | 2.48e-03 | 1.09e-02 | 115 |
GO:00703045 | Oral cavity | OSCC | positive regulation of stress-activated protein kinase signaling cascade | 66/7305 | 128/18723 | 2.58e-03 | 1.13e-02 | 66 |
GO:00716758 | Oral cavity | OSCC | regulation of mononuclear cell migration | 60/7305 | 115/18723 | 2.78e-03 | 1.21e-02 | 60 |
GO:00703735 | Oral cavity | OSCC | negative regulation of ERK1 and ERK2 cascade | 43/7305 | 78/18723 | 2.80e-03 | 1.22e-02 | 43 |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
GO:00192167 | Oral cavity | OSCC | regulation of lipid metabolic process | 154/7305 | 331/18723 | 3.00e-03 | 1.30e-02 | 154 |
GO:0070227 | Oral cavity | OSCC | lymphocyte apoptotic process | 40/7305 | 72/18723 | 3.21e-03 | 1.38e-02 | 40 |
GO:00024333 | Oral cavity | OSCC | immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:00380963 | Oral cavity | OSCC | Fc-gamma receptor signaling pathway involved in phagocytosis | 18/7305 | 27/18723 | 3.34e-03 | 1.42e-02 | 18 |
GO:00024312 | Oral cavity | OSCC | Fc receptor mediated stimulatory signaling pathway | 21/7305 | 33/18723 | 3.63e-03 | 1.51e-02 | 21 |
GO:20001061 | Oral cavity | OSCC | regulation of leukocyte apoptotic process | 44/7305 | 81/18723 | 3.66e-03 | 1.51e-02 | 44 |
GO:005087010 | Oral cavity | OSCC | positive regulation of T cell activation | 104/7305 | 216/18723 | 3.76e-03 | 1.55e-02 | 104 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516920 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0466612 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa051207 | Cervix | CC | Epithelial cell signaling in Helicobacter pylori infection | 24/1267 | 70/8465 | 4.35e-05 | 3.09e-04 | 1.83e-04 | 24 |
hsa04062 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa046115 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa05169110 | Cervix | CC | Epstein-Barr virus infection | 57/1267 | 202/8465 | 7.30e-07 | 7.39e-06 | 4.37e-06 | 57 |
hsa0466613 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0512014 | Cervix | CC | Epithelial cell signaling in Helicobacter pylori infection | 24/1267 | 70/8465 | 4.35e-05 | 3.09e-04 | 1.83e-04 | 24 |
hsa040621 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa0461113 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa0516930 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa0516730 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa052039 | Esophagus | HGIN | Viral carcinogenesis | 53/1383 | 204/8465 | 2.58e-04 | 2.71e-03 | 2.15e-03 | 53 |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa05169114 | Esophagus | HGIN | Epstein-Barr virus infection | 55/1383 | 202/8465 | 5.13e-05 | 6.19e-04 | 4.92e-04 | 55 |
hsa05167114 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LYN | SNV | Missense_Mutation | | c.475N>A | p.Glu159Lys | p.E159K | P07948 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
LYN | SNV | Missense_Mutation | | c.627N>T | p.Lys209Asn | p.K209N | P07948 | protein_coding | tolerated(0.16) | benign(0.056) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
LYN | SNV | Missense_Mutation | | c.57N>C | p.Leu19Phe | p.L19F | P07948 | protein_coding | tolerated(0.72) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LYN | SNV | Missense_Mutation | novel | c.1096N>T | p.Arg366Trp | p.R366W | P07948 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AC-A2FM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LYN | SNV | Missense_Mutation | novel | c.1442N>C | p.Lys481Thr | p.K481T | P07948 | protein_coding | deleterious(0.01) | benign(0.432) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LYN | SNV | Missense_Mutation | | c.1508N>A | p.Ala503Asp | p.A503D | P07948 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-B6-A0I9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
LYN | SNV | Missense_Mutation | | c.1252N>A | p.Gly418Arg | p.G418R | P07948 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-E2-A155-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
LYN | SNV | Missense_Mutation | novel | c.905N>C | p.Leu302Pro | p.L302P | P07948 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LYN | SNV | Missense_Mutation | | c.20A>T | p.Lys7Ile | p.K7I | P07948 | protein_coding | deleterious(0.01) | possibly_damaging(0.482) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
LYN | SNV | Missense_Mutation | | c.907G>A | p.Val303Met | p.V303M | P07948 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | CYC-116 | CYC-116 | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | ILORASERTIB | ILORASERTIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | SORAFENIB | SORAFENIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 178102666 | | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | GW459057A | GW459057A | 16890436 |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | NINTEDANIB | NINTEDANIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | NILOTINIB | NILOTINIB | 18191450 |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | MASITINIB | MASITINIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | | Bafetinib | BAFETINIB | |
4067 | LYN | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, ENZYME, CLINICALLY ACTIONABLE, DRUG RESISTANCE | inhibitor | 178103494 | IBRUTINIB | |